Mycosis Fungoides is a type of skin cancer. It starts in the skin and can sometimes spread to other parts of the body. It's a slow-growing cancer, but it can become more serious if not treated.
Every report comes from a Lived member, sent anonymously.
Have you tried Clobetasol for Mycosis Fungoides?
Mycosis fungoides is a slow-growing cancer of the immune system that shows up in the skin. It is a type of non-Hodgkin lymphoma: a group of white blood cells called T cells becomes cancerous and gathers in the skin, causing patches, raised plaques and sometimes lumps. Despite the name, it is not a fungal infection. It is the most common cutaneous T-cell lymphoma (a T-cell lymphoma that starts in the skin), although it is still rare. Most people first notice flat, scaly, reddish patches, often on areas that see little sun, such as the buttocks, trunk or breasts. The patches may itch, and in some people, particularly children, they are paler than the surrounding skin. Over time some patches thicken into plaques, and in a minority of people tumors form. Many people stay at the early patch or plaque stage for years, with the disease limited to the skin. A related condition, Sézary syndrome, causes red, itchy, peeling skin over most of the body along with large numbers of cancerous T cells in the blood. It behaves more aggressively, and experts are not sure whether it is an advanced form of mycosis fungoides or a separate disease.
The cause of mycosis fungoides is mostly unknown. Current thinking is that it starts when T cells living in the skin acquire genetic changes that let one family of them multiply unchecked, but what sets off those changes has not been established. It is diagnosed most often in older adults, and rates rise steadily with age. Men and Black Americans have been reported to have higher rates. Children and young adults can develop it, though rarely. Studies have linked sun-damaged skin, some workplace chemicals, smoking and the blood pressure medicine hydrochlorothiazide with higher rates, but these are associations, not proven causes, and most people with these exposures never develop it. It does not appear to be strongly inherited: a twin study found no increased risk in the twins of people with skin lymphoma.
Mycosis fungoides is hard to recognize early because the first patches look much like eczema, psoriasis or other common rashes, and they can come and go. Many people have a rash for several years, sometimes as long as a decade, before the diagnosis is confirmed. A rash that keeps returning in the same covered areas, or does not respond as expected to usual treatment, is often what prompts a closer look. The key test is a skin biopsy, in which a small piece of skin is removed and examined under a microscope by a pathologist, ideally one experienced in skin lymphomas. Early biopsies can be inconclusive, so more than one may be needed, sometimes over months or years. Laboratory tests on the sample help. Immunophenotyping identifies markers on the surface of the T cells, and a T-cell receptor gene rearrangement test looks for one expanded family (a clone) of T cells, which points toward lymphoma rather than ordinary inflammation. No single result settles the question; the diagnosis comes from putting the skin's appearance and the lab findings together. Once mycosis fungoides is confirmed, staging shows how far it extends. The doctor estimates how much of the skin is involved (patches or plaques covering less than 10 percent of the skin is stage IA, 10 percent or more is stage IB), examines the lymph nodes and checks the blood, including a count of cancerous T cells in the blood, called Sézary cells. Scans such as CT or PET and a lymph node biopsy are added when the disease is more extensive. Stage guides both treatment and outlook.
Treatment depends mainly on stage. For most people it aims to clear or control the skin lesions, ease itching and keep the disease from advancing, rather than to cure it. Remissions are common, but the disease often returns, so treatment tends to come in rounds over many years. Early disease limited to the skin is treated with skin-directed therapy. Strong (high-potency) corticosteroid creams or ointments are usually the first step; they clear or improve limited patches in most people but work less well for widespread or thicker disease. Light therapy (phototherapy) uses narrowband ultraviolet B, or PUVA, which combines a light-sensitizing medicine called psoralen with ultraviolet A light. It can work well for widespread patches, but it means clinic visits several times a week, and long courses of PUVA raise the later risk of skin cancer. Mechlorethamine gel (Valchlor) is a chemotherapy medicine applied to the skin for early-stage disease after another skin treatment has been tried; it often irritates the skin and must be handled so that other people do not touch it. Retinoid gels and radiation aimed at individual thick plaques or tumors are other options. When the disease is extensive, thick or has spread beyond the skin, or skin treatments stop working, medicines that act through the whole body are added, often alongside skin therapy. These include bexarotene capsules (Targretin), a vitamin A-related medicine that raises blood fats and can lower thyroid function, so it needs regular blood tests, and that causes birth defects, so it must not be used in pregnancy. Other options include low-dose methotrexate, interferon (an immune-signaling protein), histone deacetylase (HDAC) inhibitors such as vorinostat and romidepsin, and antibody-based medicines such as mogamulizumab and brentuximab vedotin. Extracorporeal photopheresis, in which some blood cells are treated with light outside the body and returned, is used especially for Sézary syndrome. Total skin electron beam therapy treats the entire skin surface with a shallow form of radiation. A stem cell transplant is considered for selected people with advanced disease, but it is intensive and carries serious risks. Clinical trials are a reasonable option at many stages. At every stage, controlling itch and caring for damaged skin are part of treatment, not an afterthought.
For most people, mycosis fungoides is a long-term condition rather than a fast-moving cancer. Most are diagnosed at an early stage, and many live with patches or plaques for years or decades. People with the most limited disease (stage IA) have a median survival of 20 years or more, and most of them die of causes unrelated to the lymphoma. About one in five people with early-stage disease eventually progress to a more advanced stage. The outlook is much more serious once there are skin tumors, redness over most of the body, or spread to the lymph nodes, blood or internal organs. In stages III and IV, median survival is about five years, and Sézary syndrome has a poorer outlook still. Being older than 60 and a rare change called large cell transformation, in which the lymphoma cells become larger and faster growing, also point to a harder course. Daily life usually centers on the skin: applying treatments, traveling for light sessions, managing itch and living with visible patches. The uncertainty of a cancer that comes and goes can be wearing, and support from people who understand it can help. Follow-up with a dermatologist or oncologist familiar with skin lymphoma is typically lifelong, with skin checks, sometimes photos to track lesions, and blood tests or scans when needed. Because the disease often returns, a flare does not necessarily mean the plan has failed; treatment is adjusted. People who have had PUVA or mechlorethamine gel also need ongoing checks for other skin cancers.
See a doctor, ideally a dermatologist, about a scaly or discolored rash that lasts for months, keeps returning in the same areas, or does not improve with treatment for eczema or psoriasis, and ask whether a biopsy is needed. If you already have mycosis fungoides, contact your care team about new lumps or tumors in the skin, redness spreading over large areas of the body, swollen lymph nodes, or itch that treatment no longer controls. Call your care team promptly for signs of skin infection, such as fever or chills, spreading redness, warmth, pus or painful blisters around lesions, because infection of broken skin is a serious complication of more advanced disease.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Mycosis Fungoides is like, what's helped you, or ask the community a question.